Trytosaveabit commented on a stock · Jan 24 08:14

Update

$AIM ImmunoTech(AIM.US)$ AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer 3 MINUTES AGO, 9:10 AM EST VIA GLOBENEWSWIRE

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

1898 Views

Comment

Trytosaveabit

1779Followers

29Following

21KVisitors